⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

January 1, 2026Therapeutic Advances in Drug SafetyOpen Access

Evaluating the patterns of use and safety of lenalidomide treatment in myelodysplastic syndromes: a European, observational multi-registry study

Iris Kim Aidan Makwana Victoria Ezenma Stefania Navarcikova Muskan Mittal Quinn Ho Hannah Borda Stefan Kaehler

View Full Paper

Ask AI

Bookmark

Share

Key Points

Lenalidomide treatment shows varying safety profiles across patients with myelodysplastic syndromes, suggesting careful monitoring is needed.
Key evidence reveals significant variations in safety outcomes based on treatment protocols and patient characteristics.
The observational multi-registry approach across Europe provides a comprehensive view of treatment patterns and safety.
Findings underscore the necessity for ongoing evaluation of treatment practices and safety measures in myelodysplastic syndromes.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Observational analysis evaluates lenalidomide treatment safety in myelodysplastic syndromes, indicating its varied usage patterns and implications.

Abstract

This study was registered with the EU Post-Authorisation Studies (PAS) Register: EUPAS22604.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kim et al. (2026) studied this question.

synapsesocial.com/papers/69a75b2ec6e9836116a220c3 https://doi.org/10.1177/20420986251407181

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Lenalidomide inhibits the malignant clone and up-regulates the <i>SPARC</i> gene mapping to the commonly deleted region in 5q− syndrome patientsOriginal Research · 2007 · 232 citations
2The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid LeukemiaReview · 2023 · 27 citations
3New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database MergePrognostic Study · 2012 · 689 citations
4Systematic Literature Review of the Global Incidence and Prevalence of Myelodysplastic Syndrome and Acute Myeloid LeukemiaSystematic Review · 2016 · 24 citations
5Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)Prognostic Study · 2011 · 282 citations

Revised International Prognostic Scoring System for Myelodysplastic Syndromes2012
Genetics of progression from MDS to secondary leukemia2020
Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy2015
Transient monocular vertical hemifield loss as a rare acute oxaliplatin-induced ophthalmological side effect: a case report and review of the literatureTherapeutic Advances in Drug Safety · 2026
Evaluation of digoxin dosing and therapeutic drug monitoring in adult patients receiving continuous venovenous hemodiafiltrationTherapeutic Advances in Drug Safety · 2026

More from Therapeutic Advances in Drug Safety

More from Bristol-Myers Squibb (Germany)

More from Bristol-Myers Squibb (Switzerland)

More from Costello Medical Consulting (United Kingdom)

More from Syneos Health (India)

More from Bristol-Myers Squibb (Ireland)